FDA Brief

Warning letters Drugs

FDA warning letter to

Catwalk Cosmetic Laboratories Pty Ltd.

High riskIssued Nov 21, 2024Posted Nov 26, 2024Center for Drug Evaluation and Research (CDER)

FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.

What happened

FDA reviewed records Catwalk submitted after FDA's March 25, 2024 request for records; this was a records review, not an inspection. FDA found missing identity testing for incoming components, missing finished-product release testing, a stability program without potency/assay testing, no process validation, and inadequate quality-unit oversight. FDA placed the firm on Import Alert 66-40 on November 18, 2024 and cited discrepancies in import entries that did not declare Catwalk as the manufacturer.

What FDA found

  1. The firm did not test each incoming component lot for identity; it relied on appearance and odor checks against the supplier's certificate.

    21 CFR 211.84(d)(1)
  2. For a high-risk component, it did not run the United States Pharmacopeia (USP) limit test for hazardous impurities, despite lethal poisoning incidents from contaminated ingredients.

    21 CFR 211.84(d)(1)
  3. It did not perform full finished-product release testing, including active ingredient identity and strength, before release.

    21 CFR 211.165(a)
  4. Its stability program omitted potency and assay testing, so it did not show products stay acceptable through expiry.

    21 CFR 211.166(a)
  5. It lacked process validation procedures or studies to show reproducible, controlled manufacturing.

    21 CFR 211.100(a)
  6. Its quality unit did not adequately approve or reject components in the materials system.

    21 CFR 211.22(a)

What FDA wants

FDA tells Catwalk to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if it cannot finish, it must give reasons and a completion schedule. FDA also recommends a qualified current good manufacturing practice consultant and says it may withhold approvals, re-inspect, or continue refusing admission.

Who should pay attention

  • U.S. importers and entry filers of Catwalk's OTC drugs
  • brands or distributors sourcing OTC creams from this manufacturer
  • quality teams auditing South African OTC drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk